Navigation Links
MannKind Corporation to Hold Second Quarter Financial Results Conference Call on August 11, 2008
Date:8/4/2008

VALENCIA, Calif., Aug. 4 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD) will release its 2008 second quarter financial results on Monday, August 11, 2008 at 4:00 p.m. EDT.

Management of the Company will host a conference call to discuss the second quarter financial results, clinical progress and other Company developments at 5:00 p.m. EDT on Monday, August 11, 2008. Presenting from the Company will be its Chairman and Chief Executive Officer, Alfred Mann; President and Chief Operating Officer, Hakan Edstrom; Corporate Vice President and Chief Financial Officer, Matthew Pfeffer and Corporate Vice President and Chief Scientific Officer, Peter Richardson.

To participate in the live call by telephone, please dial (888) 677-5721 or (210) 839-8507. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at http://www.mannkindcorp.com.

A telephone replay of the call will be accessible for approximately fourteen days following completion of the call by dialing (800) 219-6350 or (402) 220-3904. A replay will also be available on MannKind's website for fourteen days.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Its lead product, the Technosphere Insulin System, is currently in Phase 3 clinical trials in the United States
'/>"/>

SOURCE MannKind Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. MannKind to Present at the UBS Global Life Sciences Conference
2. MannKind Corporation Raises $250 Million in Self Managed Registered Direct Offerings of Common Stock
3. MannKind Announces Positive Results from a Phase 1a Study of a GLP-1 Formulation
4. MannKind to Present at the Piper Jaffray Healthcare Conference
5. MannKind to Present at the Wachovia 2008 Healthcare Conference
6. MannKind to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
7. MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on March 4, 2008
8. MannKind Corporation Response to Recent Market Events
9. Matthew J. Pfeffer Joins MannKind as Corporate Vice President and Chief Financial Officer
10. MannKind Corporation to Hold First Quarter Financial Results Conference Call on May 5, 2008
11. MannKind to Present at the Morgan Stanley Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... China Biologic Products, Inc. (NASDAQ: CBPO, ... integrated plasma-based biopharmaceutical company in China ... Shandong Taibang Biological Products Co. Ltd., has received ... Food and Drug Administration (the "CFDA") for its ... in the Company,s public filings, the CFDA inspected ...
(Date:12/24/2014)... , Dec. 23, 2014  NeuroLifeSciences announced today ... in children with attention deficit/hyperactivity disorder published in ... The paper, titled "Pilot Phase 2 ... ( Konofal et al, Drug Des Devel ... shows that mazindol might be an effective, well-tolerated, ...
(Date:12/22/2014)... 2014 GenomeDx Biosciences today announced that a ... a genomic test for prostate cancer, was able to ... by radical prostatectomy without adjuvant therapy. Although rapid metastasis ... using tumor genomics to identify these men who have ... important advance. The study has been published online ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 Bioject ... developer and manufacturer of needle-free injection technology, today ... with Immunomic Therapeutics, Inc. (“ITI”) for ITI to ... with its LAMP™ vaccine platform. , In ... exclusive Worldwide license to the Biojector®-2000 that triggers ...
Breaking Biology Technology:China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3
... , RICHMOND, Calif., Sept. 16 Sangamo BioSciences, ... Sangamo,s president and CEO, will provide an update on the progress ... company,s business strategy at 1:30 pm ET on Wednesday, September 23, ... held in New York City. , , The ...
... ANTONY, France, September 16 Stallergenes S.A.,has ... trial,(VO59.08) conducted in allergic rhinitis caused by birch pollen and,concerning ... of this pollen, rBet v 1. , ... recombinant allergen as an active,substance. To Stallergenes, knowledge, the use ...
... Sept. 16 /PRNewswire-Asia/ -- Fortis Healthcare, one of ... broaden inclusion,criteria for its upcoming diabetic foot clinical ... peripheral blood to treat critical limb ischemia,(diabetic foot). ... management, risk reduction and lengthy rehabilitation. The current,treatments ...
Cached Biology Technology:Sangamo BioSciences Announces Presentation at the UBS Global Life Sciences Conference 2STALLERGENES: Immunotherapy Tablet Containing Recombinant Allergen (rBet v 1) of Birch Pollen: Positive Results for a Phase IIb/III Trial 2STALLERGENES: Immunotherapy Tablet Containing Recombinant Allergen (rBet v 1) of Birch Pollen: Positive Results for a Phase IIb/III Trial 3STALLERGENES: Immunotherapy Tablet Containing Recombinant Allergen (rBet v 1) of Birch Pollen: Positive Results for a Phase IIb/III Trial 4Indian Stem Cell Trial to Broaden Diabetic Foot Inclusion Criteria 2Indian Stem Cell Trial to Broaden Diabetic Foot Inclusion Criteria 3Indian Stem Cell Trial to Broaden Diabetic Foot Inclusion Criteria 4
(Date:12/22/2014)...  NXT-ID, Inc. (NASDAQ: NXTD and ... focused on the growing mobile commerce market, announces it ... Apollo Robbins for the 2015 International CES debut ... Apollo Robbins will be at the NXT-ID ... some of his famous theft techniques to visiting media ...
(Date:12/22/2014)...  The 2014 Holiday Season may be the ... Market Intelligence reports that the long anticipated floodgates ... forecasts that intensifying demand for smart phones, tablets, ... drive a global market of 2.5 billion users ... According to Maxine Most ...
(Date:12/19/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/86ncd6/micro_market ) has ... North America Perimeter Security Systems Market" report to ... The North American perimeter security market is ... 2014 to 2019. Although the U.S. market holds a ... is expected to grow at a higher CAGR ...
Breaking Biology News(10 mins):NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3
... WI, SEPTEMBER 7, 2010 The American Society of ... Soil Science Society of America (SSSA) will present the ... on Oct. 31-Nov. 3 in Long Beach, CA, ... , , The Hank Beachell Future Leader ...
... research on how genes affect responses to medicines, the National ... to expand a key resource, the Pharmacogenomics Knowledge Base (PharmGKB), ... is to use information about a patient,s genetic make-up to ... grown, so has PharmGKB. Begun in 2000 to catalog links ...
... St. Louis, MO Current research provides a novel ... LaBranche et al, "Characterization of the KRN cell transfer model ... the K/BxN mouse," appears in the September 2010 issue of ... of the population is affected by rheumatoid arthritis, and women ...
Cached Biology News:ASA, CSSA and SSSA present scholarships and fellowships 2ASA, CSSA and SSSA present scholarships and fellowships 3ASA, CSSA and SSSA present scholarships and fellowships 4ASA, CSSA and SSSA present scholarships and fellowships 5ASA, CSSA and SSSA present scholarships and fellowships 6ASA, CSSA and SSSA present scholarships and fellowships 7ASA, CSSA and SSSA present scholarships and fellowships 8ASA, CSSA and SSSA present scholarships and fellowships 9NIH expands key pharmacogenomics resource 2Casing the joint 2
Rabbit polyclonal to FLIP ( Abpromise for all tested applications). entrezGeneID: 8837 SwissProtID: O15519...
... to Asparagine synthetase ( Abpromise ... Antigen: ... in the C-terminus of Human ... Entrez GeneID: 440 ...
Fluorescein isothiocyanate (FITC) mouse anti-human IFN-alpha2 25 tests...
Mouse monoclonal [M7-PB-E9] to pan alpha Sodium Potassium ATPase ( Abpromise for all tested applications)....
Biology Products: